These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 36550917)

  • 1. Efficacy and safety of Kanglaite plus EGFR-TKI in the treatment of advanced non-small cell lung cancer: A meta-analysis of 13 RCTs.
    Li D; Li W; Xu L; Che Y; Cheng C
    Medicine (Baltimore); 2022 Dec; 101(50):e32169. PubMed ID: 36550917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kanglaite Combined With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy for Stage III/IV Non-Small Cell Lung Cancer: A PRISMA-Compliant Meta-Analysis.
    Kong F; Wang C; Li X; Jia Y
    Front Pharmacol; 2021; 12():739843. PubMed ID: 34588988
    [No Abstract]   [Full Text] [Related]  

  • 3. Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Liu ZL; Zhu WR; Zhou WC; Ying HF; Zheng L; Guo YB; Chen JX; Shen XH
    J Integr Med; 2014 Jul; 12(4):346-58. PubMed ID: 25074884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials.
    Li D; Yao L; Xu L; Li W; Che Y
    Medicine (Baltimore); 2022 Dec; 101(48):e32164. PubMed ID: 36482605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kanglaite injection plus platinum-based chemotherapy for stage III/IV non-small cell lung cancer: A meta-analysis of 27 RCTs.
    Huang X; Wang J; Lin W; Zhang N; Du J; Long Z; Yang Y; Zheng B; Zhong F; Wu Q; Ma W
    Phytomedicine; 2020 Feb; 67():153154. PubMed ID: 31926475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Meta-analysis on effectiveness and safety of traditional Chinese medicine combined with first-generation EGFR-TKI in treating advanced non-small cell lung cancer].
    He W; Cheng M
    Zhongguo Zhong Yao Za Zhi; 2017 Jul; 42(13):2591-2598. PubMed ID: 28840704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials.
    Xiao YY; Zhan P; Yuan DM; Liu HB; Lv TF; Song Y; Shi Y
    Eur J Clin Pharmacol; 2013 Feb; 69(2):151-9. PubMed ID: 22729611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of Kanglaite injection combined with first-line platinum-based chemotherapy in patients with advanced NSCLC: a systematic review and meta-analysis of 32 RCTs.
    Li J; Li HZ; Zhu GH; Gao RK; Zhang Y; Hou W; Li J
    Ann Palliat Med; 2020 Jul; 9(4):1518-1535. PubMed ID: 32692199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-Analysis of Aidi Injection and First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy in Treating Advanced Non-Small Cell Lung Cancer.
    Xiao N; He H; Wang J; Zhang L; Chow B; Feng F; Xu Y; Huang J; Zhou X; Dong R
    J Evid Based Integr Med; 2021; 26():2515690X211010733. PubMed ID: 33926244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of kanglaite injection in combination with gefitinib versus gefitinib alone in patients with nonsmall cell lung cancer: A meta-analysis.
    Hailang H; Jiping Z; Ailing C; Xianmei Z
    J Cancer Res Ther; 2020; 16(4):745-751. PubMed ID: 32930113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis.
    Yu Z; Xu F; Zou J
    Eur J Clin Pharmacol; 2024 Apr; 80(4):505-517. PubMed ID: 38300281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kanglaite injection plus chemotherapy versus chemotherapy alone for non-small cell lung cancer patients: A systematic review and meta-analysis.
    Liu X; Xu F; Wang G; Diao X; Li Y
    Curr Ther Res Clin Exp; 2008 Oct; 69(5):381-411. PubMed ID: 24692815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of seven randomized control trials to assess the efficacy and toxicity of combining EGFR-TKI with chemotherapy for patients with advanced NSCLC who failed first-line treatment.
    Xiao BK; Yang JY; Dong JX; Ji ZS; Si HY; Wang WL; Huang RQ
    Asian Pac J Cancer Prev; 2015; 16(7):2915-21. PubMed ID: 25854383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis].
    Hong C; Mei T; Wang J
    Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):837-846. PubMed ID: 27978869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis.
    Yi L; Fan J; Qian R; Luo P; Zhang J
    Int J Cancer; 2019 Jul; 145(1):284-294. PubMed ID: 30613959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational Application of First-Line EGFR-TKIs Combined with Antiangiogenic Inhibitors in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Ma JT; Guo YJ; Song J; Sun L; Zhang SL; Huang LT; Jing W; Zhao JZ; Han CB
    Biomed Res Int; 2021; 2021():8850256. PubMed ID: 33575349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of bevacizumab combined with EGFR-TKIs in advanced non-small cell lung cancer: A meta-analysis.
    Yang Y; Wang L; Li X; Zhang S; Yu J; Nie X; Liu W; Wu X; Zhang P; Li Y; Li A; Ai B
    Thorac Cancer; 2022 Jan; 13(1):31-37. PubMed ID: 34859599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Qi YT; Hou Y; Qi LC
    Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
    Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
    Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.